ArticleFrontiers in endocrinology2026
Association between steatotic liver disease subtype and thyroid cancer in women: A nationwide population-based cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate association between steatotic liver disease (SLD) subtype and thyroid cancer in women using a nationwide population-based cohort. Methods: This nationwide population-based cohort study included 2,089,609 women aged more than 40 years who participated in the 2009 health screening program and were followed up until 2022. Participants were divided into four groups based on their SLD status: no SLD, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD). Results: During a mean follow-up of 12.27 years, 40,072 (1.92%) women were newly diagnosed with thyroid cancer. Compared with the no SLD group, women with MASLD had a higher risk of thyroid cancer (hazard ratio [HR]: 1.19, 95% confidence interval [CI]: 1.16-1.22), whereas those with MetALD and ALD did not have a higher risk. The risk of thyroid cancer was higher in women with MASLD, including both premenopausal (HR: 1.21, 95% CI: 1.16-1.26) and postmenopausal women (HR: 1.17, 95% CI: 1.14-1.21). Women in the MetALD group showed no risk elevation of thyroid cancer regardless of their menopausal status. Postmenopausal women in the ALD group had a higher risk of thyroid cancer than those in the no SLD group (HR: 1.31, 95% CI: 1.05-1.64), whereas premenopausal women did not have a higher risk. Conclusions: Thyroid cancer risk was modestly increased in women with MASLD, whereas no significant associations were observed for MetALD or ALD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.